Phenotypic characterization of Acinetobacter baumannii isolates in a high-complexity healthcare institution in the city of Cali;Caracterización fenotípica de aislamientos de Acinetobacter baumannii en una institución de salud de alta complejidad de Cali

Biomedica

Volumn 34, Issue SUPPL.1, 2014, Pages 101-107

  Prado, Alfredo ^a   Arias, Nhora L ^a   Chávez, Mónica ^a,b   Cabrera, Cristina E ^a,c   Gómez, Romel F ^a  

^a UNIVERSIDAD LIBRE   (Colombia)

^b UNIVERSIDAD SANTIAGO DE CALI   (Colombia)

^c UNIVERSIDAD DEL VALLE   (Colombia)

Author keywords

Acinetobacter baumannii; Cross infection,Microbial sensitivity tests; Drug resistance,Microbial

Indexed keywords

ACINETOBACTER; ACINETOBACTER BAUMANNII;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; CHILD; COLOMBIA; CROSS INFECTION; CROSS-SECTIONAL STUDY; DRUG EFFECTS; FEMALE; GENETICS; HOSPITAL; HOSPITAL DEPARTMENT; HUMAN; INFECTIOUS DISEASE MEDICINE; INTENSIVE CARE UNIT; INTERNAL MEDICINE; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MULTIDRUG RESISTANCE; PEDIATRICS; PHENOTYPE; POSTOPERATIVE COMPLICATIONS; SEASON; STATISTICS AND NUMERICAL DATA; TERTIARY CARE CENTER; UNIVERSITY HOSPITAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; CHILD; COLOMBIA; CROSS INFECTION; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITAL DEPARTMENTS; HOSPITALS, UNIVERSITY; HOSPITALS, URBAN; HUMANS; INFECTIOUS DISEASE MEDICINE; INTENSIVE CARE UNITS; INTERNAL MEDICINE; MALE; PEDIATRICS; PHENOTYPE; POSTOPERATIVE COMPLICATIONS; SEASONS; TERTIARY CARE CENTERS;

EID: 84907365450     PISSN: 01204157     EISSN: None     Source Type: Journal    
DOI: 10.7705/biomedica.v34i0.1666     Document Type: Article

References (35)

1. Peleg A, Seifert H, Paterson D. Acinetobacter baumannii emergence of a successful pathogen. Clin Microbiol Rev. 2008;2:538-82. http://dx.doi/10.1128/CMR.00058-07
2. Diomedi A. Infecciones por Acinetobacter baumannii panresistente. Consideraciones epidemiologicas y de manejo antimicrobiano actualizado. Rev Chil Infectol. 2005;22:298-320. http://dx.doi.org/10.4067/S0716-10182005000600003
3. Berlau BJ, Aucken HM, Houang E, Pitt TL. Isolation of Acinetobacter spp. Including A. baumannii from vegetables implications for hospital-acquired infections. J Hosp Infect. 1999;42:201-4. http://dx.doi.org/10.1053/jhin.1999.0602
4. Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii a universal threat to public health. Int J Antimicrob Agents. 2008;32:106-19. http://dx.doi.org/10.1016/j.ijantimicag.2008.02.013
5. Villegas MV, Kattan J, Correa A, Lolans K, Guzmán AM, Woodford N. Dissemination of Acinetobacter baumannii clones with OXA-23 carbapenemase in Colombian hospitals. Antimicrob Agents Chemother. 2007;51:2001-4. http://dx.doi.org/10.1128/AAC.00226-07
6. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010;65:233-8.http://dx.doi.org/10.1093/jac/dkp428
7. Valentine SC, Contreras D, Tan S, Real LJ, Chu S, Howard X. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County California. J Clin Microbiol. 2008;46:2499-507. http://dx.doi.org/10.1128/JCM.00367-08
8. Hart M, Llanes N, Espinosa F, Halley MC, Martínez ML, López AL. Estudio de la sensibilidad antimicrobiana de la especie Acinetobacter baumanii en el Hospital "Hermanos Ameijeiras", año 2006. Rev Cubana Med. 2008;47:1-9.
9. Organización Panamericana de Salud. Informe anual de la Red de Monitoreo de Vigilancia de la Resistencia a los Antibióticos. OPS/HDM/CD/A/541/09 2009. Washington, D.C.: Organización Panamericana de la Salud; 2011.
10. Pinzón JO, Mantilla JR, Valenzuela EM, Fernández F, Álvarez CA, Osorio EJ. Caracterización molecular de aislamientos de Acinetobacter baumannii provenientes de la unidad de quemados de un hospital de tercer nivel de Bogotá. Infectio. 2006;10:71-8.
11. Miranda MC. Estudio de la epidemiología molecular y de los factores de riesgo asociados a aislamiento de Acinetobacter baumannii en pacientes hospitalizados en el Hospital Univer-sitario del Valle (tesis). Cali: Universidad del Valle ; 2005.
12. Chávez M, Salazar M, Cabrera C, Gómez R, Pallares C. Bacterias resistentes a los antibióticos en infecciones nosocomiales de un hospital en Colombia. Enf Inf Microbiol. 2012;33:19-25.
13. Matta L, Martínez DM, Rendón LF, León H. Comportamiento de las infecciones nosocomiales en la Corporación Comfenalco Valle - Universidad Libre (julio de 2009 - junio de 2010). Rev Col Salud Libre. 2010;8:100-7.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth Informational Supplement. Wayne, PA: CLSI; 2007.
15. Montero JC, Ortíz E, Fernández T, Cayuela A, Marque J, García A, et al. Acinetobacter baumannii ventilator-associated pneumonia: Epidemiological and clinical findings. Intensive Care Med. 2005;31:649-55. http://dx.doi.org/10.1007/s00134-005-2598-0
16. Gallegoa L, Canduelaa MJ, Sevillanoa E, Pujanaa I, Calvobf F, Adelai F. Detección de carbapenemasas en clones de Acinetobacter baumannii resistentes a imipenem. Enferm Infec Microbiol Clin. 2004;22:262-6.
17. Picazo JJ, Betriu C, Rodríguez-Avial I, Culebras E, Gómez M, López F. Antimicrobial resistance surveillance: VIRA STUDY 2006. Enferm Infecc Microbiol Clin. 2006;24:617-28.
18. von Dolinger de Brito D, Oliveira EJ, Abdallah VO, da Costa Darini AL, Gontijo Filho PP. An outbreak of Acinetobacter baumannii septicemia in a neonatal intensive care unit of a university hospital in Brazil. Braz J Infect Dis. 2005;9:301-9. http://dx.doi.org/10.1590/S1413-86702005000400006
19. Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin investig Drugs. 2002;3:218-24.
20. Navia MM, Ruiz J, Vila J. Characterization of an integron carrying a new class D betalactamase (OXA-37) in Acinetobacter baumannii. Microb Drug Resist. 2002;8:261-5. http://dx.doi.org/10.1089/10766290260469516
21. Bou G, Martínez-Beltrán J. Cloning nucleotide sequencing and analysis of the gene encoding an AmpC β-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother. 2000;44:428-32. http://dx.doi.org/10.1128/AAC.44.2.428-432.2000
22. Danes C, Navia MM, Ruiz J, Marco F, Jurado A, Jiménez de Anta MT. Distribution of β-lactamases in Acinetobacter baumannii clinical isolates band the effect of Syn 2190 (AmpC inhibitor) in the mics of different beta-lactam antibiotics. J Antimicrob Chemother. 2002;50:261-4. http://dx.doi.org/10.1093/jac/dkf092
23. Vila J, Ruiz J, Navia M, Becerril B, García I, Perea S. Spread of amikacin resistance in Acinetobacter baumannii strains isolated in Spain due to an epidemic strain. J Clin Microbiol. 1999;37:758-61.
24. Vila J. Mechanisms of antimicrobial resistance in Acineto-bacter baumannii. Rev Med Microbiol.1998; 9:87-97.
25. Vila J, Ruiz J, Goñi P, Jiménez de Anta MT. Mutation in the gyrA gene of quinolone resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 1995;39:1201-3.
26. Vila J, Ruiz J, Goñi P, Jiménez de Anta T. Quinolone- resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother. 1997; 39:757-62. http://dx.doi.org/10.1093/jac/39.6.757
27. Riccio ML, Franceschini N, Boschi L, Carravelli B, Cornaglia G, Fontana R, et al. Characterization of the metallo-β-lactamase determinant of Acinetobacter baumannii a C-5 4 / 9 7 reveals the existence of blaIMP allelic variants carried by gene cassettes of different phylogeny. Antimicrob Agents Chemother. 2000;44:1229-35.
28. Chu YW, Afzal-Shah M, Houang ET, Palepou MF, Lyon DJ, Woodford N, et al. IMP-4, a novel metallo-β-lactamase from nosocomial Acinetobacter spp collected in Hong Kong between 1994 and 1998. Antimicrob Agents Chemother. 2001;45:710-4. http://dx.doi.org/10.1128/AAC.45.3.710-714.2001
29. Nordmann P, Poirel L. Acinetobacter baumannii basic and emerging mechanisms of resistance. Eur Infect Dis. 2008;2:94-7.
30. Doi Y, Paterson DL. Detection of plasmid-mediated class C ß-lactamases. Int J Infect Dis. 2007;11:191-7. http://dx.doi.org/10.1016/j.ijid.2006.07.008
31. Martínez DV. Betalactamasas tipo AmpC. Generalidades y métodos para detección fenotípica. Rev Soc Ven Microbiol. 2009;29:1315-2556.
32. Lee EH, Nicolas MH, Kitzis MD, Pialoux G, Collatz E, Gutmann L. Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem. Antimicrob Agents Chemother. 1991;35:1093-8. http://dx.doi.org/10.1128/AAC.35.6.1093
33. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid mediated AmpC betalactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother. 1997;41:563-9.
34. Fernández F, Martínez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. Relationship between betalactamase production, outer membrane protein and penicillin binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother. 2003;51:565-74. http://dx.doi.org/10.1093/jac/dkg097
35. Red de Vigilancia de Eventos Nosocomiales del Valle. Perfil Epidemiológico en 15 Instituciones IPS nivel 3 de la Ciudad de Cali, periodo enero-diciembre 2011. Fecha de consulta: 12 de febrero de 2013. Disponible en: http://www.renova.org.co/sitio/images/Presentaciones/Informe_RENOVA_2011_V5.pdf.